CDMO Avid Bioservices

Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference

Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference

TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the upcoming Craig-Hallum Bioprocessing Conference. Nick Green, president and chief executive officer, and Pramthesh Patel, Ph.D., vice president of process development, will be the featured speakers in a fireside chat at the conference, which will take place virtually on September 19, 2024.

Details of the company’s participation are as follows:

  • Craig-Hallum Bioprocessing Conference

    Details: Mr. Green and Dr. Patel will participate in a fireside chat

    Conference Date: September 19, 2024

    Fireside Chat Timing: 2:45 p.m. Eastern on Thursday, September 19, 2024

    Format: Virtual

Following the fireside chat, a webcast replay will be available via a link on Avid’s investor website at: .

About Avid Bioservices, Inc. 

Avid Bioservices (NASDAQ: CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. 



Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
 

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
 
EN
12/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avid Bioservices

 PRESS RELEASE

Avid Bioservices Launches New Company Website Designed to Boost Compan...

Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at , combines Avid’s elevated brand story and visual identity wit...

 PRESS RELEASE

Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-...

Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the “Notice”) to holders of its 7.00% Convertible Senior Notes due 2029 (the ...

 PRESS RELEASE

Avid Bioservices poised for significant growth with new partners GHO C...

Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand’s deep experience in CDMO investing to support Avid’s next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners (“Ampersand...

 PRESS RELEASE

Avid Stockholders Approve Transaction with GHO and Ampersand

Avid Stockholders Approve Transaction with GHO and Ampersand TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to approve the transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”) at the Avid special meeting of stock...

 PRESS RELEASE

Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO a...

Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders TUSTIN, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has mailed...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch